Roquefort Therapeutics plc
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with nov… Read more
Roquefort Therapeutics plc (ROQAF) - Total Assets
Latest total assets as of June 2025: $5.66 Million USD
Based on the latest financial reports, Roquefort Therapeutics plc (ROQAF) holds total assets worth $5.66 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Roquefort Therapeutics plc - Total Assets Trend (2021–2024)
This chart illustrates how Roquefort Therapeutics plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Roquefort Therapeutics plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Roquefort Therapeutics plc's total assets of $5.66 Million consist of 6.3% current assets and 93.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $5.06 Million | 88.0% |
| Goodwill | $281.91K | 4.9% |
Asset Composition Trend (2021–2024)
This chart illustrates how Roquefort Therapeutics plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Roquefort Therapeutics plc's current assets represent 6.3% of total assets in 2024, a decrease from 67.5% in 2021.
- Cash Position: Cash and equivalents constituted 5.9% of total assets in 2024, down from 19.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 92.0% of total assets, an increase from 32.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 88.0% of total assets.
Roquefort Therapeutics plc Competitors by Total Assets
Key competitors of Roquefort Therapeutics plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Roquefort Therapeutics plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Roquefort Therapeutics plc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Roquefort Therapeutics plc is currently not profitable relative to its asset base.
Roquefort Therapeutics plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.80 | 0.79 | 8.67 |
| Quick Ratio | 2.80 | 0.79 | 8.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.13 Million | $ -179.73K | $ 2.15 Million |
Roquefort Therapeutics plc - Advanced Valuation Insights
This section examines the relationship between Roquefort Therapeutics plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.43 |
| Latest Market Cap to Assets Ratio | 0.48 |
| Asset Growth Rate (YoY) | -5.5% |
| Total Assets | $5.75 Million |
| Market Capitalization | $2.73 Million USD |
Valuation Analysis
Below Book Valuation: The market values Roquefort Therapeutics plc's assets below their book value (0.48 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Roquefort Therapeutics plc's assets decreased by 5.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Roquefort Therapeutics plc (2021–2024)
The table below shows the annual total assets of Roquefort Therapeutics plc from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $5.75 Million | -5.55% |
| 2023-12-31 | $6.09 Million | -21.62% |
| 2022-12-31 | $7.77 Million | +70.35% |
| 2021-12-31 | $4.56 Million | -- |